Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy.

Autor: Carver AB; Specialty Pharmacy Services, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Zuckerman AD; Specialty Pharmacy Services, Vanderbilt University Medical Center, Nashville, Tennessee, USA., DeClercq J; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Choi L; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Chastain CA; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jazyk: angličtina
Zdroj: Open forum infectious diseases [Open Forum Infect Dis] 2020 Nov 26; Vol. 7 (12), pp. ofaa569. Date of Electronic Publication: 2020 Nov 26 (Print Publication: 2020).
DOI: 10.1093/ofid/ofaa569
Abstrakt: Rates of persistent viremia (PV) while on direct-acting antiviral therapy were low (5.7%) in a real-world cohort of 983 patients. High sustained virologic response rates were achieved both in patients with PV (92.9%) and those with rapid virologic response (96.5%), without significant differences.
(© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje